IDLDX Share Price Performance
Recent IDLDX News & Updates
No updates
IDL Diagnostics AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 21, 2025
- Earnings per share (EPS)
- -0.19
- Gross Margin
- 20.13%
- Net Profit Margin
- -73.86%
- Debt/Equity Ratio
- 0%
IDL Diagnostics AB (publ) Competitors
About IDLDX
- Founded
- 2000
- Employees
- 20
- CEO
- WebsiteView website
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Swedish Market Performance
- 7 Days: -3.5%
- 3 Months: 1.1%
- 1 Year: -0.4%
- Year to Date: -1.5%
Over the last 7 days, the market has dropped 3.5%, driven by pullbacks in every sector, especially the Industrials sector. Although the market performance has been flat over the past year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading